Methods and compositions for increasing antibody production

Details Methods and compositions for increasing antibody production Methods and compositions for increasing antibody production

2006-05-22

2010-02-02

Ouspenski, Ilia (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S328000, C435S070210

Reexamination Certificate

active

07655783

ABSTRACT:
The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. The invention further provides compositions, kits and articles of manufacture for practicing methods of the present invention.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5264365 (1993-11-01), Georgiou et al.
patent: 5264586 (1993-11-01), Nicolaou et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5508192 (1996-04-01), Georgiou et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5639635 (1997-06-01), Joly et al.
patent: 5648237 (1997-07-01), Carter
patent: 5648260 (1997-07-01), Winter et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 5854027 (1998-12-01), Steipe et al.
patent: 5892019 (1999-04-01), Schlom et al.
patent: 6027888 (2000-02-01), Georgiou et al.
patent: 6083715 (2000-07-01), Georgiou et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6455279 (2002-09-01), Ambrosius et al.
patent: 6602688 (2003-08-01), Opper et al.
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 2005/0048572 (2005-03-01), Reilly et al.
patent: 2005/0152894 (2005-07-01), Krummen et al.
patent: 2005/0170464 (2005-08-01), Simmons et al.
patent: WO 89/01974 (1989-03-01), None
patent: WO 92/22583 (1992-12-01), None
patent: WO 94/29531 (1994-12-01), None
patent: WO 95/14779 (1995-06-01), None
patent: WO 99/25378 (1999-05-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/64460 (1999-12-01), None
patent: WO 02/056910 (2002-07-01), None
patent: WO 02/061090 (2002-08-01), None
patent: WO 03/074569 (2003-09-01), None
patent: WO 2004/042017 (2004-05-01), None
patent: WO 2005/027966 (2005-03-01), None
Aruffo et al., “CD44 is the Principal Cell Surface Receptor for Hyaluronate” Cell 61:1303-1313 (Jun. 29, 1990).
Ashkenazi et al., “Immunoadhesins” Intern. Rev. Immunol. 10:219-227 (1993).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin” Proc. Natl. Acad. Sci. 88:10535-10539 (Dec. 1991).
Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library” J.Mol.Biol. 270(1):26-35 (1997).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera” The Journal of Biological Chemistry 266(34):23060-23067 (1991).
Berg et al., “Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain” Proc. Natl. Acad. Sci. USA 88:4723-4727 (Jun. 1991).
Brekke O H et al., “The structural requirements for complement activation by IgG: does it hinge on the hinge?” Immunol Today 16(2):85-90 (Feb. 1995).
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G\sub I \nor fragments” Science 229:81-83 (Jul. 5, 1985).
Byrn et al., “Biological Properties of a CD4 Immunoadhesin” Nature 344:667-670 (Apr. 12, 1990).
Canevari et al., “Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody” J Natl Cancer Inst. 87(19):1463-1469 (Oct. 4, 1995).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy” Nature 337:525-531 (Feb. 9, 1989).
Carpenter et al., “Non-Fc Receptor-Binding Humanized Anti-CD3 Antiibodies Induce Apoptosis of Activated T Cells” J. Immunol. 165:6205-6213 (2000).
Carter, “Bispecific human IgG by design” J Immunol Methods 248(1-2):7-15 (Feb. 1, 2001).
Chalupny et al., “T-cell activation molecule 4-1 BB binds to extracellular matrix proteins” Proc. Natl. Acad. Sci. USA 89(21):10360-10364 (Nov. 1992).
Cunningham and Wells, “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis” Science 244:1081-1085 (Jun. 2, 1989).
Davis, A. et al., “Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the μ heavy chain”,The EMBO Journal, 8(9):2519-2526 (1989).
Dietsch et al., “Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions” Journal of Immunological Methods 162:123-132 (1993).
Duncan et al., “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG.” Nature 332:563-564 (Apr. 7, 1988).
Ellman et al., “Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins” Meth. Enzym. 202:301-336 (1991).
Fanger et al., “Bispecific Antibodies” Critical Reviews in Immunology 12(3,4):101-124 (1992).
Gascoigne et al, “Secretion of a chimeric T-cell receptor-immunoglobulin protein” Proc Natl Acad Sci U S A. 84(9):2936-2940 (May 1987).
Gazzano-Santoro et al., “A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody” Journal of Immunological Methods. 202(2):163-171 (Mar. 28, 1997).
Gillies et al., “Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities” Hum. Antibod. Hybridomas 1(1):47-54 (1990).
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed inEscherichia coli” Journal of Immunology 152:5368-5374 (1994).
Hammerling et al., “Use of hybrid antibody with anti-\147G and anti-ferritin specificities in locating cell surface antigens by electron microscopy” Journal of Experimental Medicine 128:1461-1469 (1968).
Harris, “Production of humanized monoclonal antibodies for in vivo imaging and therapy” Biochemical Society Transactions 23:1035-1038 (1995).
Hayden et al., “Antibody engineering” Curr Opin Immunol. 9(2):201-212 (Apr. 1997).
Hollinger et al., ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments” Proc. Natl. Acad. Sci. USA 90:6444-6448 (Jul. 1993).
Hsieh-Ma et al., “In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III” Cancer Research 52(24):6832-6839 (Dec. 15, 1992).
Hsu et al., “A Humanized Anti-CD3 Antibody,HuM291, With Low Mitogenic Activity, Mediates Complete And Reversible T-Cell Depletion in chimpanzees” Transplantation 68(4):545-554 (1999).
Hurle and Gross, “Protein Engineering Techniques for Antibody Humanization” Curr. Op. Biotech. 5:428-433 (1994).
Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgGI Fc” J. Immunol. 164(8):4178-4184 (2000).
Jefferis et al., “Glycosylation of antibody molecules: structural and functional significance” Chem. Immunol. 65:111-128 (1997).
Jefferis et al., “IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation” Immunol Rev. 163:59-76 (1998).
Jefferis et al., “Interaction sites on human IgG-Fc for FcgammaR: current models” Immunol. Lett. 82(1-2):57-65 (2002).
Karpovsky et al., “Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies” J Exp Med. 160(6):1686-1701 (Dec. 1, 1984).
Klei

Affiliated with

Also associated with

Rating

Methods and compositions for increasing antibody production does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for increasing antibody production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for increasing antibody production will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4188567